



Corrigendum: Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials

Ibrahim Jantan*, Waqas Ahmad and Syed Nasir Abbas Bukhari

Drug and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

Keywords: immunomodulation, curcumin, resveratrol, epigallocatechol-3-gallate, quercetin, colchicine, capsaicin

A Corrigendum on

Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials by Jantan, I., Ahmad, W., and Bukhari, S. N. A. (2015). *Front. Plant Sci.* 6:655. doi: 10.3389/fpls.2015.00655

In the original article “Fürst and Zündoft, 2014” was not cited in the article. The citation has now been inserted in section Immunomodulators, Paragraph 3 and should read:

“Recently the clinical potential of six plant-derived anti-inflammatory compounds: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate (EGCG), and quercetin has been highlighted Fürst and Zündoft (2014). The present review will give an overview of these widely investigated plant-derived compounds including andrographolide and genistein, which have exhibited potent effects on cellular and humoral immune functions in pre-clinical investigations and will highlight their clinical potential.”

The citation has now been inserted in section Curcumin, Paragraph 2 and should read:

“However, Fürst and Zündoft (2014) suggested that these are preliminary clinical trials which are frequently too weak and of low quality to draw a conclusion due to the low number of enrolled patients, which normally ranges from 10 to 30. As suggested by the authors, more operationally thorough and serious randomized controlled trials are required to evaluate the compound as an effective and safe agent for human use. It is worth mentioning that curcumin suffers from its low bioavailability, though substantial improvement has been made to address this issue via chemical and technological methods (Anand et al., 2007).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

OPEN ACCESS

Approved by:

Frontiers in Plant Science,
Frontiers Media SA, Switzerland

*Correspondence:

Ibrahim Jantan
profilbj@gmail.com

Specialty section:

This article was submitted to
Plant Metabolism and Chemodiversity,
a section of the journal
Frontiers in Plant Science

Received: 16 July 2018

Accepted: 23 July 2018

Published: 13 August 2018

Citation:

Jantan I, Ahmad W and Bukhari SNA
(2018) Corrigendum: Plant-derived
immunomodulators: an insight on their
preclinical evaluation and clinical trials.
Front. Plant Sci. 9:1178.
doi: 10.3389/fpls.2018.01178

REFERENCES

- Anand, P., Kunnumakkara, A. B., Newman, R. A., and Aggarwal, B. B. (2007). Bioavailability of curcumin: problems and promises. *Mol. Pharm.* 4, 807–818. doi: 10.1021/mp700113r
- Fürst, R., and Zündoft, I. (2014). Plant-derived anti-inflammatory compounds: Hopes and disappointments regarding the translation of preclinical knowledge into clinical progress. *Mediat. Inflamm.* 2014: 146832. doi: 10.1155/2014/146832

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Jantan, Ahmad and Bukhari. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.